cash flow management & funding managementAs has been discussed recently and I agree, NPH has done a great job in the first part of finance above, namely cash flow management (operations)...actually perfect in my opinion and huge huge credit to Arun and co for this. .The second part of finance is funding management and this is the area I think NPH has to put equal prudence towards (as they have shown in cash flow management) , going forwards....
I think NPH will be compared against Biosyent (RX) for at least the next year or so, as for a comparable successful company in the Canadian small cap pharma sector.... If you look at RX it is a very financially conservative company regarding both funding management and cash flow management... In the very near future analysts will focus heavily on both aspects of financial management looking at NPH and also using RX (stellar in this area) as a close comparable in the sector... Also , corporate governance, which is closely related, will also be weighed heavily by analysts... For these crucial reasons it is important at this early stage that NPH carefully chooses how it proceeds on all financial matters IMO.....Congrats to management to date; but continued focus in the future equally important...